Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR

Metser, Ur; Ortega, Claudia; Perlis, Nathan; Lechtman, Eli; Berlín, Alejandro; Anconina, Reut; Eshet, Yael; Chan, Rosanna; Veit-Haibach, Patrick; Liu, Amy; Ghai, Sangeet

doi:10.1007/s00259-021-05355-7

Cited by 19 publications

(44 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In study NCT03149861, piflufolastat F 18 PSMA PET detected more clinically significant prostate cancer than mpMRI in men (n = 55) with suspicion of prostate cancer or who were being considered for focal ablative therapies, but at low specificity. However, the combination of piflufolastat F 18 PET and mpMRI was more effective than mpMRI alone in detecting clinically significant prostate cancer in PI-RADS ≥ 3 lesions [24].…”

Section: Piflufolastat F 18 Technologymentioning

confidence: 84%

“…The addition of piflufolastat F 18 PET to multiparametric MRI (mpMRI) was more effective than mpMRI alone in detecting clinically significant prostate cancer in two studies (NCT03181867 [23] and NCT03149861 [24]). In a subgroup of 70 patients in study NCT03181867, sensitivity, specificity and PPV findings with piflufolastat F 18 PET/CT imaging (69%, 91% and 86%, respectively) were comparable with those seen with mpMRI (69%, 74% and 69%).…”

Section: Piflufolastat F 18 Technologymentioning

confidence: 99%

See 1 more Smart Citation

Piflufolastat F 18: Diagnostic First Approval

Keam

2021

Mol Diagn Ther

View full text Add to dashboard Cite

Piflufolastat F 18 (PYLARIFY ® ) is an 18 F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA). Piflufolastat F 18 was approved in the USA on 27 May 2021 for PET of PSMA positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate specific antigen (PSA) level. This article summarizes the milestones in the development of piflufolastat F 18 leading to this approval as a radioactive diagnostic agent in prostate cancer.

show abstract

Section: Piflufolastat F 18 Technologymentioning

confidence: 84%

Section: Piflufolastat F 18 Technologymentioning

confidence: 99%

Piflufolastat F 18: Diagnostic First Approval

Keam

2021

Mol Diagn Ther

View full text Add to dashboard Cite

show abstract

“…In total, we included five prospective cohort studies involving 497 patients who underwent PSMA-PET-TB [19][20][21][22][23]. Two studies included only biopsy-naïve patients [19,20] and the remaining three studies included patients undergoing repeat biopsy or both biopsy-naïve and repeat-biopsy patients [21][22][23]. The characteristics of these studies are presented in Tables 1 and 2.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography–targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis

Kawada

Yanagisawa

Rajwa

et al. 2022

European Urology Oncology

View full text Add to dashboard Cite

“…However, both tracers are excreted rapidly through the urinary tract, resulting in strong accumulation in the bladder and blurring the prostate. 18 F-PSMA-7Q is a novel quinoline-containing PSMA PET tracer d e v e l o p e d b y o u r t e a m , which is mainly excreted through the liver (9). Since 18 F-PMA-7Q is rarely excreted in the urine, the incidence of false positives in the prostate may be reduced.…”

Section: Introductionmentioning

confidence: 99%

“…Since 18 F-PMA-7Q is rarely excreted in the urine, the incidence of false positives in the prostate may be reduced. However, it remains unknown whether 18 F-PMA-7Q PET can replace prostate biopsies in the diagnosis of prostate cancer. This study is a retrospective analysis to determine whether 18 F-PSMA-7Q PET/CT can replace prostate biopsy for the diagnosis of prostate cancer, and under which circumstances this can be used.…”

Section: Introductionmentioning

confidence: 99%

Can 18F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?—A single-center retrospective study

Liu¹,

Niu²,

Luan³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

Background: Of the currently available prostate-specific membrane antigen (PSMA) positron emission tomography (PET) tracers, although 68 Ga-PSMA-11 and 18 F-DCFPyL have been approved by the US Food and Drug Administration (FDA), both tracers are excreted rapidly through the urinary tract, resulting in strong accumulation in the bladder and blurring the prostate. 18 F-PSMA-7Q is a novel quinoline-containing PSMA PET tracer developed by our team, which is primarily excreted through the liver. It can reduce the incidence of urine-induced false-positives in the prostate. We aimed to explore the diagnostic efficacy of 18 F-PSMA-7Q PET/computed tomography (CT), and when 18 F-PSMA-7Q PET/CT can be used instead of prostate biopsy to diagnose prostate cancer.Methods: Patients who underwent 18 F-PSMA-7Q PET/CT for prostate cancer staging or prostate biopsy guidance at our institution between July 2020 and December 2021 were retrospectively enrolled. Molecular imaging PSMA (miPSMA) scores were assigned for intra-prostatic lesions according to the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria, and the diagnostic efficacy of 18 F-PSMA-7Q PET/CT for different miPSMA scores was evaluated using pathological diagnosis as the gold standard.Results: Of the 125 enrolled patients, 101 had prostate cancer, and 24 had prostatic hyperplasia or prostatitis. miPSMA ≥2 was the optimal diagnostic threshold, and area under curve (AUC) was 0.948, the sensitivity and specificity were 91.1% and 83.0%. The prostate cancer detection rates of 18 F-PSMA-7Q PET/CT were 14.3% (3/21), 60.0% (6/10), 96.7% (58/60), and 100% (34/34) for patients with miPSMA scores of 0, 1, 2, and 3, respectively. There was no significant difference in the detection rate of prostate cancer between groups with miPSMA scores of 2 and 3, but there were significant differences between any other 2 groups. Conclusions:The prostate cancer detection rate of 18 F-PSMA-7Q PET/CT was high for lesions with greater miPSMA scores of 2 and 3. For patients with a high miPSMA score, particularly those with a miPSMA score of 3, prostate biopsy can be omitted and prostate cancer-related treatment can be considered.

show abstract

Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR

Cited by 19 publications

References 34 publications

Piflufolastat F 18: Diagnostic First Approval

Piflufolastat F 18: Diagnostic First Approval

Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography–targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis

Can 18F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?—A single-center retrospective study

Contact Info

Product

Resources

About